On November 17, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the targeted therapy neladalkib (Nelkarmi, GSK). It is approved to treat adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with:
One prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or
Two or more prior ALK TKIs and platinum-based chemotherapy
In the United States, there will be an estimated 176,646 cases of NSCLC in 2026. It is the most common type of lung cancer. Around 5% of all people with NSCLC have genetic changes to a gene called anaplastic lymphoma kinase. When this happens, it is considered ALK-positive NSCLC. These patients tend to be younger non-smokers.
“Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years. Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients,” said Alice Shaw, MD, of Dana-Farber Cancer Institute in a press release about the approval.
How does neladalkib treat ALK-positive NSCLC?
Neladalkib is a type of targeted therapy that blocks a gene that affects cell growth. The ALK gene. Neladalkib is an ALK-sensitive tyrosine kinase inhibitor (TKI), and is also called an ALK inhibitor.
People with ALK-positive NSCLC have genetic changes called an ALK fusion or ALK rearrangement. This mutation helps cancer cells grow out of control. ALK mutations can be present at diagnosis, which is considered a native mutation. They can also develop during treatment. This is called a resistance mutation.
Neladalkib blocks both native and resistance ALK mutations. It also can move through the central nervous system. This is important to treat ALK-positive NSCLC that has spread to the brain.
Neladalkib is considered a selective ALK inhibitor. Some drugs that target ALK mutations can also affect proteins called tropomyosin receptor kinase (TRK). This can cause neurological side effects. Neladalkib does not affect TRK proteins.
Neladalkib is an oral medication. It is taken once a day. The standard dose is 150mg, but it can be adjusted if there are significant side effects.
ALKOVE-1: The study that led to the neladalkib approval
This approval was based on the phase 1/2 ALKOVE-1 clinical trial. Which had results of 67 patients with metastatic NSCLC treated with one prior ALK TKI (alectinib) and 155 patients treated with two or more prior ALK TKIs and platinum-based chemotherapy.
Among patients who received one prior ALK TKI, the overall response rate was 49%. Of those, 76% had a response duration of 6 months or more, and 52% had a response duration of 12 months or more.
Among patients who received two or more prior ALK TKIs and platinum-based chemotherapy, the overall response rate was 32%. Of those, 69% had a response duration of 6 months or more, and 51% had a response duration of 12 months or more.
What are the common side effects of neladalkib?
The most common side effects of neladalkib were:
Liver damage (hepatotoxicity)
Muscle and bone pain
Constipation
Taste changes
Swelling
Fatigue
A small number of patients (5%) stopped treatment with neladalkib due to side effects. Liver damage was the most common reason people discontinued the treatment.
Questions to ask your care team about neladalkib for ALK-positive NSCLC
If you or a loved one has ALK-positive NSCLC, ask your healthcare team about neladalkib or ongoing clinical trials. Consider asking your care team the following questions:
Did I have biomarker testing done on my tumor?
Do I have ALK-positive NSCLC?
Am I eligible for neladalkib based on my biomarkers and treatment history?
How does this treatment compare to other options available to me?
SOURCES:


